{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T02:18:50Z","timestamp":1777515530090,"version":"3.51.4"},"reference-count":13,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":5881,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.1093\/annonc\/mdg491","type":"journal-article","created":{"date-parts":[[2003,11,20]],"date-time":"2003-11-20T16:42:18Z","timestamp":1069346538000},"page":"1732-1734","source":"Crossref","is-referenced-by-count":36,"title":["European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme"],"prefix":"10.1016","volume":"14","author":[{"given":"M.J.","family":"van den Bent","sequence":"first","affiliation":[]},{"given":"W.","family":"Grisold","sequence":"additional","affiliation":[]},{"given":"D.","family":"Frappaz","sequence":"additional","affiliation":[]},{"given":"R.","family":"Stupp","sequence":"additional","affiliation":[]},{"given":"J.P.","family":"Desir","sequence":"additional","affiliation":[]},{"given":"T.","family":"Lesimple","sequence":"additional","affiliation":[]},{"given":"C.","family":"Dittrich","sequence":"additional","affiliation":[]},{"given":"M.J.A.","family":"de Jonge","sequence":"additional","affiliation":[]},{"given":"A.","family":"Brandes","sequence":"additional","affiliation":[]},{"given":"M.","family":"Frenay","sequence":"additional","affiliation":[]},{"given":"A.F.","family":"Carpentier","sequence":"additional","affiliation":[]},{"given":"P.","family":"Chollet","sequence":"additional","affiliation":[]},{"given":"J.","family":"Oliveira","sequence":"additional","affiliation":[]},{"given":"B.","family":"Baron","sequence":"additional","affiliation":[]},{"given":"D.","family":"Lacombe","sequence":"additional","affiliation":[]},{"given":"M.","family":"Schuessler","sequence":"additional","affiliation":[]},{"given":"P.","family":"Fumoleau","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdg491_bb0010","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1054\/bjoc.2000.1316","article-title":"A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse","volume":"83","author":"Yung","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdg491_bb0015","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1008382516636","article-title":"Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse","volume":"12","author":"Brada","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdg491_bb0020","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1073\/pnas.95.6.2914","article-title":"Transport of the new chemotherapeutic agent \u03b2-d-glucosylisophopharmide mustard (D-19575) into tumor cells is mediated by the Na+-d-glucose cotransporter SAAT1","volume":"95","author":"Veyhl","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"Abstr 468","key":"10.1093\/annonc\/mdg491_bb0025","first-page":"118a","article-title":"Phase I clinical and pharmacokinetic study of glufosfamide administered as a short time infusion every three weeks in patients with solid tumors","volume":"20","author":"Depenbrock","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdg491_bb0030","first-page":"3444","volume":"18","author":"Briasoulis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg491_bb0035","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.1990.8.7.1277","article-title":"Response criteria for phase II studies of supratentorial malignant glioma","volume":"8","author":"Macdonald","year":"1990","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg491_bb0040","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.1999.17.9.2762","article-title":"Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse","volume":"17","author":"Yung","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg491_bb0045","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedures for phase II clinical trials","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"key":"10.1093\/annonc\/mdg491_bb0050","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"10.1093\/annonc\/mdg491_bb0055","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/BF00163542","article-title":"Cerebral herniation in patients receiving cisplatin","volume":"6","author":"Walker","year":"1988","journal-title":"J Neuro-Oncol"},{"key":"10.1093\/annonc\/mdg491_bb0060","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1200\/JCO.1998.16.6.2188","article-title":"Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American brain tumor consortium report","volume":"16","author":"Chang","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg491_bb0065","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1200\/JCO.1999.17.5.1516","article-title":"Irinotecan therapy in adults with recurrent or progressive malignant glioma","volume":"17","author":"Friedman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdg491_bb0070","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0959-8049(00)00165-9","article-title":"Health related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide","volume":"36","author":"Osoba","year":"2000","journal-title":"Eur J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419642468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419642468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/14\/12\/1732\/395437\/mdg491.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T21:17:34Z","timestamp":1582233454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419642468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":13,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["S0923753419642468"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdg491","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2003,12]]}}}